



LEADING THE DEVELOPMENT OF MODERN MEDICINE


RESVERLOGIX CORP. (TSX:RVX) is a late-stage biotechnology company with a leadership position in **EPIGENETICS** - dedicated to improving the lives of patients with chronic illnesses

Apabetalone is an entirely new epigenetic therapeutic, taken orally to improve the condition of people suffering from vascular diseases by regulating the expression of disease-related genes.

In February 2020, **apabetalone** was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) following the groundbreaking findings of **BETonMACE**, the first ever Phase 3 trial of a BET inhibitor, outside of oncology.



APABETALONE - BET INHIBITOR FOR THE REDUCTION OF MACE



: ir@resverlogix.com



: 403.254.9252




: www.resverlogix.com



: @Resverlogix_RVX


TSX:RVX

THE FUTURE OF DRUG DEVELOPMENT



While most people are familiar with the inheritance of genes via DNA from one generation to the next, fewer realize the activity of these genes is determined by **epigenetics**, which literally means “on top of” genetics. DNA contains the code that tells our cells what to do, and this instruction manual is the same in every cell and does not change with time. Epigenetic modifications determine which instructions are read and how often each is executed. Via this mechanism, gene activity may be turned up or down like a dimmer switch, allowing cells to specialize into their numerous roles throughout the body. Epigenetic control over the genetic instructions also underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines, such as **apabetalone**.

APABETALONE CLINICAL TRIAL HISTORY



BETonMACE Overview

BETonMACE, initiated in 2015, included 2,425 patients in 13 countries. The trial was completed in September 2019, and results were presented at the 2019 AHA Scientific Sessions. The addition of **apabetalone** to standard of care therapy after acute coronary syndrome in patients with T2DM and low HDL cholesterol, although not reaching statistical significance, showed a strong trend towards a reduction in MACE. Statistical significance was reached in the pre-specified reallly-impaired subgroup, with an observed hazard reduction of 50%. The pre-specified secondary endpoint of first hospitalization for congestive heart failure (CHF) was reduced by 41% with **apabetalone**. When CHF was added to the primary endpoint post hoc, a hazard reduction of 21% was measured. Exciting new findings in the trial revealed potential synergy between **apabetalone** and two other classes of drugs, SGLT2 inhibitors and DPP4 inhibitors.

News Highlights

June 3, 2021 - Resverlogix and EVERSANA™ announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved.

April 12, 2021 - Resverlogix announced that it has successfully received its desired “No Objection Letter” from Health Canada. It has approved the COVID-19 Clinical Trial Application for apabetalone. The planned Phase 2 trial will be an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19.

Analysts

Roth Capital Partners: Jerry Isaacson, PhD

Van Leeuwenhoek Research: Marcel Wijma, MSc

Zacks: John Vandermosten, CFA

Financial Profile

- Shares O/S (MM): ~238.7
- Share Price: \$0.66
- Market Cap (MM): ~\$159.5
- 52 week high/Low: \$1.52/\$0.64
- Total Cash Raised (MM): ~\$520

Notes:

*As at 08-08-2021

*All figures in CAD\$